文献速递艾滋病与性传播感染

早期治疗HIV-1感染者换用多替拉韦单药治疗48周期间未发现前病毒进化

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks.
PubMed 文献 · J Infect Dis · 2023-01-01

本研究对一项随机临床试验中早期治疗并换用多替拉韦单药治疗或继续联合抗逆转录病毒治疗的HIV-1感染者,采用近全长前病毒PCR和下一代测序分析纵向外周血单核细胞样本,评估前病毒进化和耐药突变出现情况。两组均未检测到遗传距离或多样性随时间增加,单个前病毒分析显示高比例缺陷病毒和低数量耐药突变,未发现多替拉韦单药治疗期间前病毒进化的证据。

要点

  • 早期治疗HIV-1感染者换用多替拉韦单药治疗48周,未检测到前病毒遗传距离或多样性增加。
  • 单个前病毒分析显示高比例缺陷前病毒和低数量耐药突变。
  • 两组间关于前病毒进化证据的潜在差异未在摘要中报告具体数值。

核心结论

  • 在这些早期治疗的个体中,未发现多替拉韦单药治疗期间前病毒进化的证据。

研究设计与样本

  • 本研究对一项随机临床试验中早期治疗并换用多替拉韦单药治疗或继续联合抗逆转录病毒治疗的HIV-1感染者,进行纵向前病毒分析。
  • 应用近全长HIV-1前病毒聚合酶链反应和下一代测序于纵向外周血单核细胞样本。

主要发现

  • 两个治疗组均未检测到遗传距离或多样性随时间增加。
  • 单个前病毒分析显示高比例缺陷前病毒和低数量耐药突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human immunodeficiency virus type 1 (HIV-1) infection is treated with antiretroviral therapy (ART), usually consisting of 2-3 different drugs, referred to as combination ART (cART). Our recent randomized clinical trial comparing a switch to dolutegravir monotherapy with continuation of cART in early-treated individuals demonstrated sustained virological suppression over 48 weeks. Here, we characterize the longitudinal landscape of the HIV-1 reservoir in these participants, with particular attention to potential differences between treatment groups regarding evidence of evolution as a proxy for low-level replication. Near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing was applied to longitudinal peripheral blood mononuclear cell samples to assess proviral evolution and the potential emergence of drug resistance mutations (DRMs). Neither an increase in genetic distance nor diversity over time was detected in participants of both treatment groups. Single proviral analysis showed high proportions of defective proviruses and low DRM numbers. No evidence for evolution during dolutegravir monotherapy was found in these early-treated individuals.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Jörimann L, Tschumi J, Zeeb M, et al. Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks. J Infect Dis. 2023. PMID: 37498738. doi:10.1093/infdis/jiad292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。